

SUPPLEMENT FOR: Pembrolizumab for the first-line treatment of recurrent locally advanced or metastatic Merkel cell carcinoma: results from the single-arm, open-label, phase III KEYNOTE-913 study

AUTHORS: Laurent Mortier^a, Lisa Villabona^b, Ben Lawrence^c, Ana Arance^d, Marcus O. Butler^e, Marie Beylot-Barry^f, Philippe Saiag^g, Mahtab Samimi^h, Paolo A. Asciertoⁱ, Francesca Spada^j, Michel De Pontville^k, Michele Maio^l, Alfonso Berrocal^m, Enrique Espinosaⁿ, Jaume Capdevila^o, Max Levin^p, Debasmita Das^q, Clemens Krepler^q, Dmitri Grebennik^q, Vanna Chiarion Sileni^r

AFFILIATIONS: ^aUniversité Lille, CHRU Lille, 42 rue Paul Duez, Lille, France;

laurent.mortier@chru-lille.fr

^bKarolinska University Hospital, Karolinska Vägen 22, Stockholm, Sweden;

lisa.villabona@sll.se

^cUniversity of Auckland, 34 Princes Street, Auckland, New Zealand;

benjaminla@adhb.govt.nz

^dHospital Clinic Barcelona and IDIBAPS, C. de Villarroel, 170 Barcelona, Spain;

amarance@clinic.cat

^ePrincess Margaret Cancer Centre, 27 King's College Cir, Toronto, ON, Canada'

marcus.butler@uhn.ca

^fCentre Hospitalier Universitaire de Bordeaux, INSERM 1312, 1 Rue Jean Burguet,

Bordeaux, France; marie.beylot-barry@chu-bordeaux.fr

^gHôpital Ambroise Paré, APHP & EA4340, University of Versailles-SQY, and Paris-Saclay

University, 9 Av. Charles de Gaulle, Boulogne-Billancourt, France; philippe.saiag@uvsq.fr

^hUniversity of Tours, France; ISP1282 INRA University of Tours, 60 Rue du Plat d'Étain,

Tours, France; mahtab.samimi@univ-tours.fr

ⁱIstituto Nazionale Tumori IRCCS Fondazione "G. Pascale," Via Mariano Semmola, 53,

Naples, Italy; paolo.ascierto@gmail.com

^jIstituto Europeo di Oncologia (IEO) IRCCS, Milan, Via Giuseppe Ripamonti, 435, Italy;
francesca.spada@ieo.it

^kCentre Hospitalier Universitaire de Caen – Hôpital Côte de Nacre, Av. de la Côte de Nacre
CS 30001, Caen, France; m.de-pontville@baclesse.unicancer.fr

^lUniversity of Siena and Center for Immuno-Oncology, University Hospital of Siena, Siena,
Italy; mmaiocro@gmail.com

^mHospital General Universitario de Valencia, Avda. Tres Cruces, 2, Valencia, Spain;
berrocal.alf@gmail.com

ⁿHospital Universitario La Paz, CIBERONC, P.º de la Castellana, 261, Madrid, Spain;
eespinosa00@hotmail.com


^oVall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Pg. de la Vall
d'Hebron, 119; Barcelona, Spain; jcapdevila@vhio.net

^pUniversity of Gothenburg and Sahlgrenska University Hospital, Universitetsplatsen 1,
Gothenburg, Sweden; Max.Levin@wlab.gu.se

^qMerck & Co., Inc., 120 E. Lincoln Ave, Rahway, NJ, USA; debasmita.das1@merck.com,
clemens.krepler@merck.com, dmitri.grebennik@merck.com

^rIstituto Oncologico Veneto IOV-IRCCS, Via Gattamelata, 64, Padua, Italy;
vanna.chiarion@iov.veneto.it

Fig. S1. Change from baseline over time in the sum of target lesions per RECIST v1.1 by BICR



Abbreviations: BICR, blinded independent central review; RECIST v1.1, Response Evaluation Criteria in Solid Tumors, version 1.1.

Table S1**Immune-mediated adverse events and infusion reactions.**

	All patients (n = 55)	
Immune-mediated adverse events and infusion reactions		
Any	14 (25)	
Grade 3–5	3 (5)	
Serious	3 (5)	
Led to discontinuation	5 (9)	
Led to death	1 (2) ^a	
Immune-mediated adverse events	Any grade	Grade 3–5
Hyperthyroidism	3 (5)	0
Hypothyroidism	3 (5)	0
Colitis	2 (4)	1 (2)
Hypophysitis	2 (4)	0
Pneumonitis	2 (4)	0
Adrenal insufficiency	1 (2)	0
Encephalitis	1 (2)	1 (2)
Guillain-Barré syndrome	1 (2)	1 (2)
Nephritis	1 (2)	0
Severe skin reaction	1 (2)	0

Data are n (%).

Adverse events of interest were based on a list of terms specified by the sponsor and were considered regardless of attribution to study treatment.

^aOne patient died of Guillain-Barré syndrome that was considered related to treatment.

Table S2**Ethics committees and reference numbers**

IRB Name	Reference Number
Biomedical Research Alliance of New York IRB	3475-913-004
NYU School of Medicine IRB	3475-913-006
University Health Network Research Ethics Board	3475-913-0051
Horizon Health Network Research Ethics Board	3475-913-0055
CPP Sud-Ouest et Outre-Mer I	3475-913-0200 3475-913-0201 3475-913-0202 3475-913-0203 3475-913-0204
Comitato Etico Istituto Oncologico Veneto	3475-913-0221
Comitato Etico INT Pascale	3475-913-0222
Comitato Etico degli IRCCS Istituto Europeo di Oncologia e Centro Cardiologico Monzino	3475-913-0223
Comitato Etico Regione Toscana - Area Vasta Sud Est	3475-913-0224
CEIm de la Comunidad Foral de Navarra C/ Irunlarrea 3	3475-913-0261 3475-913-0262 3475-913-0263 3475-913-0264
Regionala Etikprovningssamnden Goteborg	3475-913-0281 3475-913-0282
St. Vincents Hospital Sydney HREC	3475-913-0400
Hunter New England Human Research Ethics Committee	3475-913-0402
Southern Health And Disability Ethics Committee	3475-913-0427